ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
116.99
+0.82 (+0.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close116.17
Open116.01
Bid0.00 x 800
Ask0.00 x 800
Day's Range115.81 - 117.25
52 Week Range102.10 - 149.34
Volume989,812
Avg. Volume1,366,675
Market Cap26.072B
Beta1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.45
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est159.17
Trade prices are not sourced from all markets
  • Alexion's BLA for ALXN1210 Gets Priority Review From FDA
    Zacks16 hours ago

    Alexion's BLA for ALXN1210 Gets Priority Review From FDA

    The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.

  • Investor's Business Daily2 days ago

    Stocks Jump At Starting Bell As This Dow Stock Retakes Buy Point

    Nike and Alexion Pharmaceuticals staked out early leads Monday, as strength across global markets helped boost stocks in opening trade.

  • Business Wire2 days ago

    FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US

    Alexion Pharmaceuticals, Inc. (ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA) for approval of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). The Phase 3 clinical development program of ALXN1210 is the largest-ever Phase 3 program in PNH.

  • What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
    Market Realist9 days ago

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.

  • Biotech ETFs in Focus on String of Q2 Earnings Beat
    Zacks12 days ago

    Biotech ETFs in Focus on String of Q2 Earnings Beat

    Biotech ETFs draw attention post impressive Q2 results.

  • Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals
    Market Realist13 days ago

    Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals

    In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.

  • How Did Jazz Pharmaceuticals Perform in the Second Quarter?
    Market Realist14 days ago

    How Did Jazz Pharmaceuticals Perform in the Second Quarter?

    On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.

  • GlobeNewswire14 days ago

    Recent Analysis Shows Washington Real Estate Investment Trust, FirstEnergy, Alexion Pharmaceuticals, Alaska Air Group, Fortune Brands Home & Security, and Baxter International Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington ...

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Analysts Are Bullish on Sarepta Therapeutics
    Market Realist15 days ago

    Analysts Are Bullish on Sarepta Therapeutics

    Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.

  • ALXN vs. RGNX: Which Stock Is the Better Value Option?
    Zacks16 days ago

    ALXN vs. RGNX: Which Stock Is the Better Value Option?

    ALXN vs. RGNX: Which Stock Is the Better Value Option?

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of ALXN earnings conference call or presentation 26-Jul-18 12:00pm GMT

    Q2 2018 Alexion Pharmaceuticals Inc Earnings Call

  • 5 Stocks Trading Near 52-Week High With More Upside in Store
    InvestorPlace21 days ago

    5 Stocks Trading Near 52-Week High With More Upside in Store

    Quite often, investors start wondering if this level has made a stock an overpriced one. In fact, a decision to avoid stocks that are trading near their 52-week high levels makes an investor miss out on most of the top gainers. This is because investors fear that the stocks are overvalued and a price crash is impending.

  • 5 Stocks Trading Near 52-Week High With More Upside in Store
    Zacks21 days ago

    5 Stocks Trading Near 52-Week High With More Upside in Store

    Here are some stocks trading near their 52-week high levels with potential to scale higher.

  • What Alnylam’s Bottom Line Is Expected to Look Like in Q2 2018
    Market Realist22 days ago

    What Alnylam’s Bottom Line Is Expected to Look Like in Q2 2018

    Alnylam Pharmaceuticals’ (ALNY) selling, general, and administrative expenses are expected to rise 73.46% from $45.78 million in the second quarter of 2017 to $79.41 million in the second quarter of 2018, and its research and development expenses are also expected to rise 22.75% from $90.63 million in the second quarter of 2017 to $111.25 million in the second quarter of 2018. Of the 16 analysts covering Alnylam Pharmaceuticals in July, 12 have given the stock “buy” or higher ratings, and three have given it “hold” ratings. In comparison, peers, Amgen (AMGN), Celgene (CELG), Alexion Pharmaceuticals (ALXN), and Bristol-Myers Squibb (BMY) have mean ratings of 2.3, 2.25, 1.74, and 2.55, respectively, and target prices of $203.95, $112.54, $158.89, and $57.56, respectively.

  • Vertex and Alexion Are Schooling Big Biotech
    Bloomberg27 days ago

    Vertex and Alexion Are Schooling Big Biotech

    Strong earnings reports from Vertex Wednesday afternoon and Alexion Thursday morning capped off what’s been a string of largely positive news for the companies, whose market values clock in at a not-quite-top-tier $45 billion and $30 billion, respectively.

  • Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up
    Zacks27 days ago

    Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up

    ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.

  • Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates
    Zacks27 days ago

    Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates

    Alexion beat both earnings and sales estimates in the second quarter of 2018.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates
    Zacks27 days ago

    Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates

    Alexion (ALXN) delivered earnings and revenue surprises of 22.49% and 6.55%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press27 days ago

    Alexion: 2Q Earnings Snapshot

    The New Haven, Connecticut-based company said it had a loss of $2.05 per share. Earnings, adjusted for one-time gains and costs, were $2.07 per share. The results exceeded Wall Street expectations. The ...

  • Business Wire27 days ago

    Alexion Reports Second Quarter 2018 Results

    BOSTON-- -- 2Q18 total revenues of $1,045.0 million, a 14 percent increase over 2Q17 and a 16 percent volume increase 2Q18 GAAP diluted EPS of $ per share; non-GAAP diluted EPS of $2.07 per share Filed ALXN1210 submissions for PNH approval in the U.S. and EU and on track to file in Japan in the second half of 2018 AchR Antibody-Positive Generalized Myasthenia Gravis on track to be best launch of any ...

  • 6 Stocks to Buy for Trade War Protection
    Kiplinger27 days ago

    6 Stocks to Buy for Trade War Protection

    Trade war tensions between the U.S. and China have only intensified over the past few months, causing a growing headache for investors. One day the market gains on optimism of a cease-fire between President Donald Trump and China President Xi Jinping. The next day, one or the other is threatening to slap tariffs on billions of dollars' worth of new goods. The spat began quietly enough in January, when the U.S. imposed tariffs on imports of solar cells and washing machines. As the year has progressed, America has added steel and aluminum imports to the list, then tariffs on another $34 billion in Chinese goods more recently. Numerous threats have been made in between. But the volatility this has sparked in the stock markets is creating buying opportunities in many solid companies that don't have as much to fear should the U.S. actually dive into a full-blown trade war. Particularly attractive are companies that primarily do business within the U.S. Here, the economy is accelerating, consumer spending is strong, inflation is in check and the tax cuts passed in 2017 are heavily benefiting domestic companies. With that in mind, here are six stocks to buy if you're looking for ways to grow your portfolio without worrying about a trade war. SEE ALSO: The Best and Worst Presidents (According to the Stock Market)

  • Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More
    Zacks28 days ago

    Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More

    Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.

  • What Clovis’s Bottom Line Is Expected to Look Like In Q2 2018
    Market Realist28 days ago

    What Clovis’s Bottom Line Is Expected to Look Like In Q2 2018

    Clovis Oncology’s (CLVS) selling, general, and administrative expenses are expected to increase by 12.48% from $36.15 million in the second quarter of 2017 to $40.66 million in the second quarter of 2018. Clovis Oncology is expected to have a net income of -$84.85 million in the second quarter of 2018 compared to a net income of -$175.39 million in the second quarter of 2017. Of the nine analysts covering Clovis Oncology in July, seven have given the stock “buy” or higher ratings, and two have given it “hold” ratings.